By Adrian Galbreth
A treatment for macular odema (MO) has been approved by the National Institute for Health and Clinical Excellence (NICE).
In its final draft guidance, NICE recommended the dexamethasone (Ozurdex, Allergan) intravitreal implant for the treatment of MO following central retinal vein occlusion (RVO).
The dexamethasone implant works by being injected into the eye once every six months and suppresses inflammation and will be particularly targeted at older people with RVO, who are the highest-risk demographic.
As RVO leads directly to MO and can cause severe visual impairment, it is hoped the drug will be able to improve eyecare across the UK.
In other eye research, Dr Charlotte Codina, who recently worked on a study which discovered that deaf people see better because their retinas develop differently, says a number of research possibilities have now been opened up.
by Alexa Kaczka